TY - JOUR
T1 - Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia
AU - Gabrielli, A.
AU - Zhang, Z. X.
AU - Cherubini, G.
AU - Candela, M.
AU - Savoldi, S.
AU - Manzin, A.
AU - Clementi, M.
AU - Amoroso, A.
AU - Sallberg, M.
PY - 1996
Y1 - 1996
N2 - In this study we have evaluated the prevalence of antibodies against core region peptides (residues 1 28, 21-38 and 51-68), the envelope 1, the non-structural (NS) 4 and 5 proteins of hepatitis C virus (HCV) in sera from 65 chronically HCV-infected patients, 47 with mixed cryoglobulinaemia (MC+) and 18 without (MC-). The major binding sites were located within the core region. Regions 1 28 and 51 68 were recognized by a similar proportion of MC+ and MC- patients, while peptide 21-38 was less frequently detected by samples from MC+ patients (65.5% versus 100%; P = 0.011). The patterns of the reactions showed a minimum of three binding sites: one, located within region 51-68, was shared by both groups, a second determinant was identified at residues 1 21 for MC+ patients and at residues 28 38 for MC- patients; a third, not exactly localized, lay between residues 1 and 38. Recognition of NS5 peptides was not significantly different between MC+ and MC- patients, but while the former mostly reacted either with peptide 1 (residues 2294- 2309) (five of 15 sera)or with peptide 2 (residues 2304-2319) (nine of 15 sera), the latter group showed a more scattered reaction. Antibodies to HCV peptides prevalently belonged to IgG1 subclass. However, whereas IgG1 antibodies against peptide 21-38 and peptide 1 of NS5 were more frequently found in MC- rather than in MC+ patients (100% versus 63.8%, P = 0.003, and 22.2% versus 4.2%, P = 0.025, respectively), IgG3 antibodies against region 1-28 were more frequent in MC+ patients (53.19% versus 16.6%, P = 0.0078). Overall, the data suggest that a differential humoral immune response to HCV antigens occurs in patients with and without cryoglobulinaemia.
AB - In this study we have evaluated the prevalence of antibodies against core region peptides (residues 1 28, 21-38 and 51-68), the envelope 1, the non-structural (NS) 4 and 5 proteins of hepatitis C virus (HCV) in sera from 65 chronically HCV-infected patients, 47 with mixed cryoglobulinaemia (MC+) and 18 without (MC-). The major binding sites were located within the core region. Regions 1 28 and 51 68 were recognized by a similar proportion of MC+ and MC- patients, while peptide 21-38 was less frequently detected by samples from MC+ patients (65.5% versus 100%; P = 0.011). The patterns of the reactions showed a minimum of three binding sites: one, located within region 51-68, was shared by both groups, a second determinant was identified at residues 1 21 for MC+ patients and at residues 28 38 for MC- patients; a third, not exactly localized, lay between residues 1 and 38. Recognition of NS5 peptides was not significantly different between MC+ and MC- patients, but while the former mostly reacted either with peptide 1 (residues 2294- 2309) (five of 15 sera)or with peptide 2 (residues 2304-2319) (nine of 15 sera), the latter group showed a more scattered reaction. Antibodies to HCV peptides prevalently belonged to IgG1 subclass. However, whereas IgG1 antibodies against peptide 21-38 and peptide 1 of NS5 were more frequently found in MC- rather than in MC+ patients (100% versus 63.8%, P = 0.003, and 22.2% versus 4.2%, P = 0.025, respectively), IgG3 antibodies against region 1-28 were more frequent in MC+ patients (53.19% versus 16.6%, P = 0.0078). Overall, the data suggest that a differential humoral immune response to HCV antigens occurs in patients with and without cryoglobulinaemia.
KW - cryoglobulinaemia
KW - hepatitis C virus
KW - immunity
KW - infection
UR - http://www.scopus.com/inward/record.url?scp=0030016033&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030016033&partnerID=8YFLogxK
M3 - Article
C2 - 8697636
AN - SCOPUS:0030016033
VL - 105
SP - 59
EP - 64
JO - Clinical and Experimental Immunology
JF - Clinical and Experimental Immunology
SN - 0009-9104
IS - 1
ER -